

## DAFTAR PUSTAKA

- Agarwal, G., Nanda, G., Lal, P., Mishra, A., Agarwal, A., Agrawal, V., & Krishnani, N. (2016). Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? *World Journal of Surgery*, 40(6), 1362–1372. <https://doi.org/10.1007/s00268-016-3422-4>
- Almansour, N. M. (2022). Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. In *Frontiers in Molecular Biosciences* (Vol. 9). Frontiers Media S.A. <https://doi.org/10.3389/fmolb.2022.836417>
- Bindea, G., Mlecnik, B., Fridman, W. H., Pagès, F., & Galon, J. (2010). Natural immunity to cancer in humans. In *Current Opinion in Immunology* (Vol. 22, Issue 2, pp. 215–222). <https://doi.org/10.1016/j.coi.2010.02.006>
- Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP. Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer. *Radiographics*. 2020 Jul-Aug;40(4):913-936. <https://doi.org/10.1148/rg.2020190181>
- Bhattacharyya, G. S., Basu, S., Agarwal, V., Malhotra, H., Pareekh, P. M., Babu, K. G., & Aggarwala, D. (2009). 41LBA Single institute phase II study of weekly cisplatin and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. *European Journal of Cancer Supplements*, 7(3), 18–19. [https://doi.org/10.1016/s1359-6349\(09\)72076-2](https://doi.org/10.1016/s1359-6349(09)72076-2)
- Burla, S., Domalpaly, B., & Begum, N. (2015). Adverse drug reaction profiles of commonly used platinum compounds in cancer chemotherapy. *International Journal of Basic & Clinical Pharmacology*, 1. <https://doi.org/10.5455/2319-2003.ijbcp20150421>
- Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., Liu, S., Cao, S., & Li, X. (2018). Association between BRCA status and triple-negative breast cancer: A meta-analysis. In *Frontiers in Pharmacology* (Vol. 9, Issue AUG). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2018.00909>
- Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. *Cold Spring Harb Perspect Biol* 2011; 3: pii: a003285, doi: 10.1101/cshperspect. a003285.
- Demaria S, Volm MD, Shapiro RL et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. *Clin Cancer Res* 2001; 7: 3025–3030.
- Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol*.
- Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009). Pattern of metastatic spread in triple-negative breast cancer. *Breast Cancer Research and Treatment*, 115(2), 423–428. <https://doi.org/10.1007/s10549-008-0086-2>

- Echavarria I, Lopez-Tarruella S, Picornell A, Garcia-Saenz JA, Jerez Y, Hoadley K, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification. *Clin Cancer Res.* 2018;24(8):1845–52. <https://doi.org/10.1158/1078-0432.CCR-17-1912>
- Egger, S. J., Chan, M. M. K., Luo, Q., & Wilcken, N. (2020). Platinum-containing regimens for triple-negative metastatic breast cancer. In *Cochrane Database of Systematic Reviews* (Vol. 2020, Issue 12). John Wiley and Sons Ltd. <https://doi.org/10.1002/14651858.CD013750>
- Faria, S. S., Giannarelli, D., Cordeiro de Lima, V. C., Anwar, S. L., Casadei, C., de Giorgi, U., Madonna, G., Ascierto, P. A., Mendoza López, R. V., Chammas, R., & Capone, M. (2023). Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics. *The Oncologist*. <https://doi.org/10.1093/oncolo/oyad303>
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5), E359–E386. <https://doi.org/10.1002/ijc.29210>
- Formenti, S. C. et al. (2017) 'Results of a phase I–II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer', *OncoImmunology*, 6(3). doi: 10.1080/2162402X.2016.1274479. Geyer, F. C. et al. The spectrum of triple-negative breast disease: high- and low- grade lesions. *Am. J. Pathol.* 187, 2139–2151 (2017).
- Hato, S. v., Khong, A., de Vries, I. J. M., & Lesterhuis, W. J. (2014). Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics. *Clinical Cancer Research*, 20(11), 2831–2837. <https://doi.org/10.1158/1078-0432.CCR-13-3141>
- Herrero-Vicent, C., Guerrero, A., Gavilá, J., Gozalbo, F., Hernández, A., Sandiego, S., Algarra, M. A., Calatrava, A., Guillem-Porta, V., & Ruiz-Simón, A. (2017). Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. *Ecancermedicalscience*, 11. <https://doi.org/10.3332/ecancer.2017.759>
- Hong, H., Wang, Q., Li, J., Liu, H., Meng, X., & Zhang, H. (2019). Aging, Cancer and Immunity. *Journal of Cancer*, 10(13), 3021–3027. <https://doi.org/10.7150/jca.30723>
- Hussein, I. A., Ahmed, S. T., Hameedi, A. D., Naji, R. Z., Alharbawi, L., Alkhaytt, M., & Pity, I. S. (2020). Immunohistochemical expression of BRCA1 protein, ER, PR and Her2/neu in breast cancer: A clinicopathological study. *Asian Pacific Journal of Cancer Prevention*, 21(4), 1025–1029. <https://doi.org/10.31557/APJCP.2020.21.4.1025>
- Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol.* 2015. [https://doi.org/10.1016/S1470-2045\(15\)70064-1](https://doi.org/10.1016/S1470-2045(15)70064-1)

- Hwang, S. Y., Park, S., & Kwon, Y. (2019). Recent therapeutic trends and promising targets in triple negative breast cancer. In *Pharmacology and Therapeutics* (Vol. 199, pp. 30–57). Elsevier Inc. <https://doi.org/10.1016/j.pharmthera.2019.02.006>
- Kalaw, E. et al. Metaplastic breast cancers frequently express immune check- point markers FOXP3 and PD-L1. *Br. J. Cancer* 123, 1665–1672 (2020).
- Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015). Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. In *Trends in Pharmacological Sciences* (Vol. 36, Issue 12, pp. 822–846). Elsevier Ltd. <https://doi.org/10.1016/j.tips.2015.08.009>
- Khan, A., Ellis, I. O., Hanby, A. M., Cosar, E. F., Rakha, E. A., & Kandil, D. (n.d.). (2018) *Precision Molecular Pathology of Breast Cancer*. <http://www.springer.com/series/7723>
- Lien, H. C. et al. (2021). Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components. *Virchows Arch.* 478, 669–678 (2021).
- Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest.* 2011;121(7):2750–67. <https://doi.org/10.1172/JCI45014>
- Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagali, D., Kellokumpu-Lehtinen, P. L., Bono, P., Kataja, V., Desmedt, C., Piccart, M. J., Loibl, S., Denkert, C., Smyth, M. J., Joensuu, H., & Sotiriou, C. (2014). Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. *Annals of Oncology*, 25(8), 1544–1550. <https://doi.org/10.1093/annonc/mdu112>
- Lotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian Shotorbani S, Jadidi Niaragh F, Baghbanzadeh A, Vahed N, Silvestris N, et al. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. *Diagnostics*. 2020; 10(9):704. <https://doi.org/10.3390/diagnostics10090704>
- Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric- Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. *Clin Cancer Res.* 2013;19(19):5533–40. <https://doi.org/10.1158/1078-0432.CCR-13-0799>
- Ma Y, Kepp O, Ghiringhelli F et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. *Semin Immunol* 2010; 22: 113–124.
- Mahdavi, M., Nassiri, M., Kooshyar, M. M., Vakili-Azghandi, M., Avan, A., Sandry, R., Pillai, S., Lam, A. K. yin, & Gopalan, V. (2019). Hereditary breast cancer; Genetic penetrance

and current status with BRCA. In *Journal of Cellular Physiology* (Vol. 234, Issue 5, pp. 5741–5750). Wiley-Liss Inc. <https://doi.org/10.1002/jcp.27464>

- Marchiò, C., Weigelt, B. & Reis-Filho, J. S. Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas). *J. Clin. Pathol.* 63, 220–228 (2010).
- Ng, B., Puspitaningtyas, H., Wiranata, J. A., Hutajulu, S. H., Widodo, I., Anggorowati, N., Sanjaya, G. Y., Lazuardi, L., & Sripan, P. (2023). Breast cancer incidence in Yogyakarta, Indonesia from 2008–2019: A cross-sectional study using trend analysis and geographical information system. *PLoS ONE*, 18(7 JULY). <https://doi.org/10.1371/journal.pone.0288073>
- Park, H. S., Heo, I., Kim, J. Y., Kim, S., Nam, S., Park, S., & Kim, S. il. (2016). No effect of tumor-infiltrating lymphocytes (TIL) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TIL Working Group 2014. *Journal of Surgical Oncology*, 114(1), 17–21. <https://doi.org/10.1002/jso.24275>
- Pruneri, G., Vingiani, A., Bagnardi, V., Rotmensz, N., de Rose, A., Palazzo, A., Colleoni, A. M., Goldhirsch, A., & Viale, G. (2016). Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. *Annals of Oncology*, 27(2), 249–256. <https://doi.org/10.1093/annonc/mdv571>
- Rathore, A. S., Kumar, S., Konwar, R., Srivastava, A. N., Makker, A., & Goel, M. M. (2013). Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. *Indian Journal of Cancer*, 50(3), 239–244. <https://doi.org/10.4103/0019-509X.118744>
- Ruan, M., Tian, T., Rao, J., Xu, X., Yu, B., Yang, W., & Shui, R. (2018). Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. *Diagnostic Pathology*, 13(1). <https://doi.org/10.1186/s13000-018-0743-7>
- Staudacher, L., Cottu, P. H., Diéras, V., Vincent-Salomon, A., Guilhaume, M. N., Escalup, L., Dorval, T., Beuzeboc, P., Mignot, L., & Pierga, J. Y. (2011). Platinum-based chemotherapy in metastatic triple-negative breast cancer: The Institut Curie experience. *Annals of Oncology*, 22(4), 848–856. <https://doi.org/10.1093/annonc/mdq461>
- Safonov, A., Casadeval, D., Qing, T., Silber, A., Killelea, B., Hatzis, C., & Pusztai, L. (2019). Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. *Breast Cancer Research and Treatment*, 175(1), 247–259. <https://doi.org/10.1007/s10549-019-05156-5>
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., van den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E. A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TIL) in breast cancer: Recommendations by an International TIL

Working Group 2014. In *Annals of Oncology* (Vol. 26, Issue 2, pp. 259–271). Oxford University Press. <https://doi.org/10.1093/annonc/mdu450>

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*, 68(1), 7–30. <https://doi.org/10.3322/caac.21442>

Takada, K., Kashiwagi, S., Asano, Y., Goto, W., Morisaki, T., Shibutani, M., Tanaka, H., Hirakawa, K., & Ohira, M. (2022). Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age. *World Journal of Surgical Oncology*, 20(1). <https://doi.org/10.1186/s12957-022-02513-5>

Teichgraeber, D. C., Guirguis, M. S., & Whitman, G. J. (2021). Breast cancer staging: Updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. In *American Journal of Roentgenology* (Vol. 217, Issue 2, pp. 278–290). American Roentgen Ray Society. <https://doi.org/10.2214/AJR.20.25223>

Uğurluoğlu, C., & Yormaz, S. (2023). Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas. *Pathology Research and Practice*, 250. <https://doi.org/10.1016/j.prp.2023.154828>

Yu, K. da, Ye, F. G., He, M., Fan, L., Ma, D., Mo, M., Wu, J., Liu, G. Y., Di, G. H., Zeng, X. H., He, P. Q., Wu, K. J., Hou, Y. F., Wang, J., Wang, C., Zhuang, Z. G., Song, C. G., Lin, X. Y., Toss, A., Shao, Z. M. (2020). Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*, 6(9), 1390–1396. <https://doi.org/10.1001/jamaoncol.2020.2965>

WHO Classification of Tumours Editorial Board. Breast Tumours: WHO Classification of Tumours, 5th Edition, 2021.

Widodo, I., Ghazali, A., Purwanto, I., & Ferronika, P. (2022). Stromal Tumor Infiltrating Lymphocytes (sTIL) Were Associated with a Higher Grade and a Lower Stage of Indonesian Triple Negative Breast Cancers. *Asian Pacific Journal of Cancer Prevention*, 23(8), 2749–2754. <https://doi.org/10.31557/APJCP.2022.23.8.2749>

Vikas, P., Borcherdig, N., & Zhang, W. (2018). The clinical promise of immunotherapy in triple-negative breast cancer. *Cancer Management and Research*, 10, 6823–6833. <https://doi.org/10.2147/CMAR.S185176>

Valenza C, Taurelli Salimbeni B, Santoro C, Trapani D, Antonarelli G, Curigliano G. Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. *Cancers*. 2023; 15(3):767. <https://doi.org/10.3390/cancers15030767>